Please confirm you are human (Sign Up for free to never see this)
← Back to Search
MRI Measurements Of Breast Tumor Volume Predict Response To Neoadjuvant Chemotherapy And Recurrence-free Survival.
S. Partridge, J. Gibbs, Y. Lu, L. Esserman, D. Tripathy, D. Wolverton, H. Rugo, E. Hwang, C. Ewing, N. Hylton
Published 2005 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
OBJECTIVE The purpose of this study was to assess the value of MRI measurements of breast tumor size for predicting recurrence-free survival (RFS) in patients undergoing neoadjuvant (preoperative) chemotherapy and to compare the predictive value of MRI with that of established prognostic indicators. SUBJECTS AND METHODS The study included 62 patients undergoing neoadjuvant chemotherapy. The longest diameter and volume of each tumor were measured on MRI before and after one and four cycles of treatment. Change in diameter on clinical examination, tumor size at pathology, and the number of positive nodes were determined. Each measure of tumor extent was assessed for the ability to predict RFS. RESULTS Univariate Cox analysis showed initial MRI volume was the strongest predictor of RFS (p = 0.002). Final change in MRI volume (p = 0.015) was more predictive than change in diameter on MRI (p = 0.077) or clinical examination (p = 0.27). Initial diameter on MRI (p = 0.003) and clinical examination (p = 0.033), tumor size at pathology (p = 0.016), and number of positive nodes (p = 0.045) were also significantly predictive of RFS. Early change in MRI volume (p = 0.071) and diameter (p = 0.081) after one chemotherapy cycle showed trends of association with RFS. Multivariate analysis showed initial MRI volume (p = 0.005) and final change in MRI volume (p = 0.003) were significant independent predictors. CONCLUSION MRI tumor volume was more predictive of RFS than tumor diameter, suggesting that volumetric changes measured using MRI may provide a more sensitive assessment of treatment efficacy.
This paper references
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H. Kuerer (1999)
Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients 1
H. Watanabe (2003)
Comparison of written reports of mammography, sonography and magnetic resonance mammography for preoperative evaluation of breast lesions, with special emphasis on magnetic resonance mammography
S. Malur (2000)
Reporting results of cancer treatment
A. Miller (1981)
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
S. Partridge (2002)
Monitoring the Size and Response of Locally Advanced Breast Cancers to Neoadjuvant Chemotherapy (Weekly Paclitaxel and Epirubicin) with Serial Enhanced MRI
Y. Cheung (2004)
CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size.
S. Sohaib (2000)
The effect of tumor size and lymph node status on breast carcinoma lethality
J. Michaelson (2003)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging
L. Martincich (2004)
Radiological Measurement of Breast Cancer Metastases to Lung and Liver: Comparison Between WHO (Bidimensional) and RECIST (Unidimensional) Guidelines
S. Prasad (2003)
Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.
L. Esserman (1999)
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.
P. Rosen (1993)
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
G. Bonadonna (1998)
Semi-automated analysis for MRI of breast tumors.
S. Partridge (1999)
Pathologic findings from the national surgical adjuvant breast project (protocol 4): Discriminants for 15‐year survival
E. Fisher (1993)
Tumor Volume Change as a Predictor of Chemotherapeutic Response in Osteosarcoma
K. Shin (2000)
Locally advanced noninflammatory breast cancer.
K. Hunt (1996)
Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography
P. Davis (2005)
Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
M. Werner-wasik (2001)
MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with x‐ray mammography and palpation
P. Weatherall (2001)
Pathologic findings from the national surgical adjuvant breast project (protocol 6) I. Intraductal carcinoma (DCIS)
E. Fisher (1986)
Measuring response in solid tumors: unidimensional versus bidimensional measurement.
K. James (1999)
MRI of breast cancer: influence of chemotherapy on sensitivity.
A. Rieber (1997)
Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent.
C. Boetes (1995)
Imaging in Evaluation of Response to Neoadjuvant Breast Cancer Treatment Benefits of MRI
C. Balu-Maestro (2004)
Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy.
R. Gilles (1994)
Survival Analysis: Techniques for Censored and Truncated Data
J. P. Klein (1997)
Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination.
S. Koscielny (1984)
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
C. Carter (1989)
Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast.
P. Drew (2001)
Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging
D. C. Abraham (1996)
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B. Fisher (1998)
Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.
E. Rosen (2003)
This paper is referenced by
Additive value of diffusion‐weighted MRI in the I‐SPY 2 TRIAL
W. Li (2019)
Place de l’imagerie dans le bilan d’extension et l’évaluation de la réponse thérapeutique des cancers du sein
J. Stines (2007)
Évaluation de la réponse aux traitements en cancérologie
Breast imaging and reporting data system (BIRADS): magnetic resonance imaging.
A. Tardivon (2007)
Handbook of Breast MRI by Jeremy Price
J. Price (2011)
Simple and robust image-based autofocusing for digital microscopy.
S. Yazdanfar (2008)
Breast conservation after neoadjuvant chemotherapy: A prognostic index for clinical decision-making
D. Holmes (2005)
Breast cancer MRI radiomics: An overview of algorithmic features and impact of inter‐reader variability in annotating tumors
Ashirbani Saha (2018)
Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer
M. Jacobs (2011)
Indications for breast magnetic resonance imaging. Consensus document “Attualità in senologia”, Florence 2007
F. Sardanelli (2008)
Role of breast MR imaging in neoadjuvant chemotherapy.
H. C. Le-Petross (2010)
Pattern recognition applied to the computer-aided detection and diagnosis of breast cancer from dynamic contrast-enhanced magnetic resonance breast images.
J. Levman (2010)
Evaluation of locoregional recurrence in patients with early breast carcinoma post-breast-conserving surgery with and without the use of preoperative chemotherapy
S. M. M. Al-Hakkak (2020)
Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy
L. Nilsen (2010)
The Current Role of Endocrine Therapy in Locally Advanced Breast Cancer to Improve Breast Conservation Rates
S. Monnier (2012)
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group.
F. Sardanelli (2010)
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL
W. Li (2016)
Breast image analysis for risk assessment, detection, diagnosis, and treatment of cancer.
M. Giger (2013)
Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast‐enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity
W. J. Choi (2018)
The effectiveness of breast MRI in invasive lobular carcinoma.
Ritse M. Mann (2010)
Optical sensing for tissue differentiation
Daniel J. Evers (2014)
Effect of Gd‐DTPA induCED susceptibility on single‐point dixon fat/water separation
Tamar Hoory (2008)
Les traitements néoadjuvants TNA (RPC 2013)
R. Salmon (2013)
MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy.
Hon J. Yu (2007)
Breast cancer response post neoadjuvant chemotherapy using MRI measurements
S. Sivaranjini (2017)
Image guided near-infrared spectroscopy of breast tissue in vivo using boundary element method.
S. Srinivasan (2010)
Voxelwise analysis of simultaneously acquired and spatially correlated 18F‐fluorodeoxyglucose (FDG)‐PET and intravoxel incoherent motion metrics in breast cancer
Jason Ostenson (2017)
Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
S. Okamoto (2015)
11-1-2010 Image Guided Near-Infrared Spectroscopy of Breast Tissue In Vivo Using Boundary Element Method
S. Srinivasan (2019)
Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy
D. Manton (2006)
Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy.
Mindy Williams (2013)
[Imaging of response to treatment in oncology].
L. Fournier (2007)See more